Scholars Central

Research articlePublished 31 May 2015

Development of rifampicin derivatives sensitive to the rpoB mutated Mycobacterium tuberculosis: An insilico approach

Authors: Santosh Kumar K., Sambandam Cecilia, Kannan, Premavathi R. K., Shantha S.

Journal of Chemical and Pharmaceutical Research

Volume 7 · Issue 5 · Pages 153–159

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The treatment of tuberculosis (TB) usually consists of administrating series of drugs over a span of six to nine months. The important drugs prescribed to TB patients are Rifampicin and Isoniazid. The activity of rifampicin is attributed to its ability to bind and inhibit the DNA dependent RNA polymerase enzyme of bacteria. Mutations conferring rifampicin resistance (RifR) map almost exclusively to the rpoB gene that produces beta subunit of RNA polymerase enzyme. The mutation thus created produces the protein which has less binding affinity for the rifampicin thus escapes the inhibitory action of the rifampicin. Thus in the present study an insilico approach has been done to modify the structure of rifampicin structure in such a way that it can bind effectively to the mutated RNA polymerase enzyme. The three dimensional structure of RNA polymerase of M. tuberculosis and its mutants are predicted by homology modelling by MODELLER software. The predicted 3D structure was then validated with the Ramachandran plot. The derivatives of the rifampicin were prepared in ACD chemsketch software. The protein – ligand docking was performed by Hex version 8.0.0. From the present study it is evident that there is possibility of preparing rifampicin derivatives that can be sensitive for the rifampicin resistant strain of M. tuberculosis. The study also has proposed four rifampicin derivatives based on binding energy values that can be sensitive to the rifampicin resistant strain of M. tuberculosis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Chemical and Pharmaceutical Research
  • SubjectPharmaceutical Sciences
  • SubjectChemistry
  • BylineArticles whose byline prints “Santosh Kumar K.”
  • BylineArticles whose byline prints “Sambandam Cecilia”
  • BylineArticles whose byline prints “Kannan”
  • BylineArticles whose byline prints “Premavathi R. K.”
  • BylineArticles whose byline prints “Shantha S.”